Dublin, Dec. 22, 2016 -- Research and Markets has announced the addition of the "Chronic Pain Drugs Price Analysis and Strategies - 2016" report to their offering.
Chronic Pain Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Chronic Pain market.
The research answers the following questions:
- What are the key drugs marketed for Chronic Pain and their clinical attributes? How are they positioned in the Global Chronic Pain market?
- What are the unit prices and annual treatment cost for Chronic Pain therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Chronic Pain drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Chronic Pain?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Chronic Pain including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Chronic Pain
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Chronic Pain market
- Chronic Pain Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Chronic Pain New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/p68dtk/chronic_pain
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Analgesics


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



